| Keli Walbert |
Keli Walbert is currently the Chief Marketing Officer & Executive Vice President at Horizon Therapeutics Plc. She has a graduate degree from Northwestern University and an undergraduate degree from the University of Louisville. |
| Vikram Karnani |
Vikram Karnani is currently the President-International, Medical Affairs & EVP at Horizon Therapeutics Plc. Previously, he worked as the VP-Therapeutics & Cell Therapy Business at Fresenius Kabi USA LLC from 2008 to 2014. He holds a graduate degree from Case Western Reserve University, an undergraduate degree from the University of Mumbai, and an MBA from Kellogg School of Management. |
| Irina P. Konstantinovsky |
Irina P. Konstantinovsky is currently the Chairman at The Human Resources Management Association of Chicago. She is also the Director at YWCA of Metropolitan Chicago since 2018 and the Chief Human Resources, EVP & Diversity Officer at Horizon Therapeutics Plc since 2017. Previously, she worked as the Director & Senior Partner at Willis Towers Watson (New York) from 1998 to 2012. She also served as the Vice President-Global Talent at Baxter International, Inc. from 2012 to 2017 and as the Chief Human Resources Officer at Capital BlueCross, Inc. from 2001 to 2003. Ms. Konstantinovsky holds a graduate degree from Cornell University and an undergraduate degree from Universidad de Buenos Aires. |
| Andy Pasternak |
Andy Pasternak is currently the Chief Strategy Officer & Executive Vice President at Horizon Therapeutics Plc. Prior to his current position, he worked as a Partner at Bain & Co., Inc. from 2008 to 2019 and as a Partner at Oliver Wyman, Inc. from 1998 to 2008. Mr. Pasternak completed his undergraduate degree at Northwestern University and holds an MBA from The University of Chicago. |
| Karin Rosen |
Karin Rosen is currently the Director at Diamyd Medical AB since 2023 and the Chief Scientific Officer at Horizon Therapeutics Plc since 2020. Previously, she worked as the Senior Vice President-US Medical Affairs at GSK Plc from 2018 to 2020. She holds a doctorate degree from the University of Lund. |
| Elizabeth H. Z. Thompson |
Presently, Elizabeth H. Z. Thompson is Executive Vice President-Research & Development at Horizon Therapeutics Plc. She is also on the board of IGM Biosciences, Inc. and California Life Sciences Association.
She previously occupied the position of Group Director-Scientific Clinical Development at AbbVie, Inc.
Dr. Thompson received an undergraduate degree from Harvey Mudd College and a doctorate from The Scripps Research Institute. |
| Aaron L. Cox |
Aaron L. Cox is currently the Chief Financial Officer & Executive Vice President at Horizon Therapeutics Plc. Previously, he worked as a Vice President-Capital Markets at BMO Capital Markets Corp. He completed his undergraduate degree at the University of Notre Dame and holds an MBA from The University of Chicago Booth School of Business. |
| Jane Gonnerman |
Jane Gonnerman is currently the Chief of Staff & Group Vice President-Development at Horizon Therapeutics Plc since 2021. Prior to this, she worked as a Partner at Bain & Co., Inc. from 2016 to 2021. She completed her MBA from The University of Chicago and her undergraduate degree from the University of Florida. |
| Patrick McIlvenny |
Patrick McIlvenny is currently working as the Chief Accounting Officer & Senior Vice President at Horizon Therapeutics Plc. He started this position in 2022. Prior to his current job, Mr. McIlvenny pursued an undergraduate degree at the University of Ulster. |
| Jeffrey W. Sherman |
Jeffrey W. Sherman is currently an Independent Director at Larimar Therapeutics, Inc. and an Independent Non-Executive Director at Xeris Biopharma Holdings, Inc. He is also a Director at Sorriso Pharmaceuticals, Inc. and a Governor-Health Section at Biotechnology Innovation Organization. Previously, he served as the Chief Medical Officer & Executive Vice President at Horizon Therapeutics Plc and Horizon Therapeutics USA, Inc. He was also a Member-Alumni Board at Feinberg School of Medicine. In his former roles, he was an Independent Non-Executive Director at Xeris Pharmaceuticals, Inc., President & Director at Drug Information Association, Independent Director at Strongbridge Biopharma Plc, Chief Medical Officer & Executive Vice President at NeoPharm, Inc., Chief Marketing Officer & Executive Vice President at Hyperion Therapeutics, Inc., Head-Oncology Global Medical Operations at Pharmacia Corp., Chief Medical Officer, SVP-Research & Development at IDM Pharma, Inc., and Vice President-Clinical Science at Takeda Global Research & Development Center, Inc. He also held positions at Howard Hughes Medical Institute, Inc., American Board of Internal Medicine, The National Board of Medical Examiners, Inc., and Horizon Pharma, Inc. Dr. Sherman received his undergraduate degree from Lake Forest College and his doctorate degree from Chicago Medical School. |
| Michael A. DesJardin |
Michael A. DesJardin is currently the Executive VP-Technical Operations & Quality at Horizon Therapeutics Plc since 2017. Previously, he was the Senior Vice President-Technical Operations at Horizon Pharmaceutical LLC from 2015 to 2016. Before that, he was the Senior Vice President-Product Development at Jazz Pharmaceuticals Plc from 2004 to 2015. He also worked as the Executive Director-Implant Research & Development at ALZA Corp. from 1995 to 2004. Mr. DesJardin completed his undergraduate degree from the University of California, Berkeley. |
| Timothy P. Walbert |
Timothy P. Walbert is currently the President & Chief Executive Officer at Horizon Therapeutics Plc and Horizon Therapeutics USA, Inc. He is also the Director at Biotechnology Innovation Organization, Pharmaceutical Research & Manufacturers of America, The Arthritis Foundation, Illinois Biotechnology Industry Organization, Horizon Pharmaceutical LLC, Exicure Operating Co., Chicagonext, Viela Bio, Inc., Mirum Pharmaceuticals, Inc., Century Therapeutics, Inc., Sagimet Biosciences, Inc., and a Trustee at Muhlenberg College. Additionally, he is a Member of the Illinois Innovation Council. In his former roles, Mr. Walbert served as the President & Chief Executive Officer at Hyperion Therapeutics, Inc., IDM Pharma, Inc., Horizon Therapeutics, Inc., and Horizon Pharma, Inc. He was also the Chairman at Zyla Life Sciences LLC, Co-Chairman at Innovation Development Institute, Inc., Chairman at Exicure, Inc., and Lead Independent Director at Assertio Therapeutics, Inc. Furthermore, he held positions as an Independent Director at XOMA Corp., Sucampo Pharmaceuticals LLC, Raptor Pharmaceuticals Corp., and Horizon Pharmaceutical LLC. He was a Director at World Business Chicago and held various roles at Celebrex North America, Abbott Laboratories, Wyeth LLC, Merck & Co., Inc., NeoPharm, Inc., and G.D. Searle & Co., Inc.Mr. Walbert obtained his undergraduate degree from Muhlenberg College. |
| Gino Santini |
Gino Santini's current jobs include being a Director at ImClone LLC since 2008, a Lead Independent Director at Collegium Pharmaceutical, Inc. since 2012, a Director at Artax Biopharma, Inc. since 2014, a Director at Intarcia Therapeutics, Inc. since 2013, and an Independent Director at Enalare Therapeutics, Inc. . His former jobs include being the Chairman at National Pharmaceutical Council, the Chairman at AMAG Pharmaceuticals, Inc. from 2014 to 2020, the Chairman at Noble of Indiana, the Lead Independent Director at Intercept Pharmaceuticals, Inc. from 2018 to 2023, an Independent Director at Inspiration Biopharmaceuticals, Inc., an Independent Director at Horizon Therapeutics Plc from 2012 to 2023, an Independent Director at Sorin SpA from 2012 to 2015, an Independent Director at Vitae Pharmaceuticals LLC from 2015 to 2016, a Director at Greater Indianapolis Chamber of Commerce, Inc., a Director at United Way of Central Indiana, Inc., a Director at Indiana Chamber of Commerce, a Director at Finanziaria Saccarifera Italo Iberica. SpA from 2013 to 2014, an Independent Director at Horizon Pharma, Inc. from 2012 to 2014, a Director at Allena Pharmaceuticals, Inc. from 2012 to 2022, and an SVP-Corporate Strategy & Business Development at Eli Lilly & Co. from 2008 to 2010. Mr. Santini's education includes an undergraduate degree from Alma Mater Studiorum - Università di Bologna in 1981, an undergraduate degree from Università di Bologna Buenos Aires in 1981, and an MBA from the University of Rochester Simon Business School in 1983. |
